Familial spinocerebellar ataxia (SCA), Huntington disease, and spinal and bulbar muscular atrophy are inherited neurodegenerative diseases. Because of their similar molecular pathogenesis, they are also called polyglutamine (polyQ) diseases. A recent systemic review shows that the global prevalence of SCA is 3 in 100,000; however, a wide regional variation exists. SCA3 is commonest subtype around the globe, SCA2 is more prevalent in Cuba than SCA3, SCA6 is one of the most common ataxia in the North of England whilst SCA7 is the most frequent subtype in Venezuela. PolyQ diseases are caused by an abnormal expansion of a specific DNA sequence consisting of the three bases: cytosine, adenine and guanine (CAG). In certain genes that are important for normal neuronal function, CAG can appear back to back multiple times. The number of CAG repetitions varies between individuals and different neuronal genes, but if the repetition happens too often, the function of the protein that is built from the gene can be severely impaired.
While an increased number of CAG repeats results in protein misfolding and aggregation with concurrent damage to nerve cells, medication that actually halts this process of neurodegeneration has yet to be developed. Current treatments for these diseases only focus on symptomatic improvement, as disease-modifying approaches have remained an unmet clinical need. Now, researchers from Osaka University, National Center of Neurology and Psychiatry, and Niigata University have identified the natural amino acid arginine as a novel potential approach to attenuate symptoms, as well as the molecular pathogenesis of polyQ diseases. In a new study published in Brain, they show how arginine improved neurological symptoms when given to mice with polyQ diseases before and even after the onset of symptoms. To achieve their goal, the researchers turned to chemical chaperones, molecules that facilitate proper protein folding, to prevent the build-up of protein aggregates.
By screening a number of chemical chaperones for their ability to prevent protein aggregation in a test tube, they discovered that arginine, a naturally occurring amino acid, had the strongest inhibiting effect on protein aggregation. In a separate set of experiments using living cells, the researchers then found that arginine was also able to prevent aggregate formation of polyQ proteins. To test the therapeutic potential of arginine, the researchers utilized well-established mouse models of familial spinocerebellar ataxia, and spinal and bulbar muscular atrophy. When added to their drinking water before symptom onset, arginine inhibited polyQ protein aggregation as well as suppressed motor impairment and neurodegeneration of the mice. Intriguingly, even after the onset of neurological symptoms, arginine was able to ameliorate the detrimental effects of familial spinocerebellar ataxia. It is remarkable that arginine can be assumed up to 2 grams daily as a supplement, without appreciable side effects.
Dr Eiko Minakawa, lead author of the study and senior author Dr. Yoshitaka Nagai commented together: “We cannot cure patients with polyglutamine diseases. Instead, we have had to resort to symptomatic therapy as the only medical option. The goal of our study was to find a new disease-modifying drug for polyglutamine diseases. Our data show how arginine could alleviate the detrimental effects of polyQ aggregate formation. These are striking results that show how arginine has therapeutic potential for familial spinocerebellar ataxia, which to date has been an incurable disease. We next wanted to know if arginine could slow down or halt the progression of different polyQ diseases in living organisms. Our next goal is to conduct clinical trials to use arginine as a novel therapy for polyglutamine diseases including spinocerebellar ataxias”.
- Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.
Minakawa EN et al., Nagai Y. Brain 2020 May 21: awaa115.
Arnold FJ, Merry DE. Neurotherapeutics 2019; 16(4):928-47.
Paulson HL et al. Nat Rev Neurosci. 2017; 18(10):613–626.
Takeuchi T, Nagai Y. Brain Sci. 2017 Oct 11; 7(10):128.